{"classes":[{"categories":[{"measurements":[{"comment":"Geometric coefficient of variation was not calculated due to single participant in the arm.","groupId":"OG000","spread":"NA","value":"3010"},{"comment":"Geometric coefficient of variation was not calculated due to single participant in the arm.","groupId":"OG001","spread":"NA","value":"6370"},{"groupId":"OG002","spread":"50.0","value":"8660"},{"groupId":"OG003","spread":"96.5","value":"14600"},{"groupId":"OG004","spread":"81.6","value":"13100"},{"groupId":"OG005","spread":"74.3","value":"25400"},{"groupId":"OG006","spread":"94.8","value":"35400"},{"comment":"Geometric coefficient of variation was not calculated due to single participant in the arm.","groupId":"OG007","spread":"NA","value":"6760"},{"groupId":"OG008","spread":"59.5","value":"11100"},{"groupId":"OG009","spread":"85.2","value":"18600"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"4"}],"units":"Participants"}],"description":"AUCtau is the area under the curve calculated to the end of a dosing interval (tau) at steady-state calculated by formula amount \\*time \\* volume\\^-1","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received 45 mg LTT462 QD as oral capsules.","id":"OG000","title":"LTT462 45 mg QD"},{"description":"Participants received 100 mg LTT462 QD as oral capsules.","id":"OG001","title":"LTT462 100 mg QD"},{"description":"Participants received 150 mg LTT462 QD as oral capsules.","id":"OG002","title":"LTT462 150 mg QD"},{"description":"Participants received 200 mg LTT462 QD as oral capsules.","id":"OG003","title":"LTT462 200 mg QD"},{"description":"Participants received 300 mg LTT462 QD as oral capsules.","id":"OG004","title":"LTT462 300 mg QD"},{"description":"Participants received 400 mg LTT462 QD as oral capsules.","id":"OG005","title":"LTT462 400 mg QD"},{"description":"Participants received 450 mg LTT462 QD as oral capsules.","id":"OG006","title":"LTT462 450 mg QD"},{"description":"Participants received 600 mg LTT462 QD as oral capsules.","id":"OG007","title":"LTT462 600 mg QD"},{"description":"Participants received 150 mg LTT462 twice daily (BID) as oral capsules.","id":"OG008","title":"LTT462 150 mg BID"},{"description":"Participants received 200 mg LTT462 BID as oral capsules.","id":"OG009","title":"LTT462 200 mg BID"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PAS included of all participants who have at least 1 PK blood sample providing measurable LTT462 and received at least 1 dose of study drug, didn't vomit within 4 hours postdose, had at least 1 primary PK parameter. Here 'N' number of participants analyzed signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Days 1, 2, 3, 8, 15 and 16; Cycle 2 day 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1","title":"The Area Under the Curve Calculated to the End of a Dosing Interval (Tau) at Steady-state (AUCtau) of LTT462","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}